AxoGen Analyst & Investor Day Nov 2017

New York, November 20, 2017

 

Please join AxoGen executives and physician thought leaders for a discussion of new clinical developments in peripheral nerve repair and the company’s growing platform for nerve repair.  

 

Revenue generating, dedicated to peripheral nerve repair with a portfolio of regenerative medicine products available in the US, Canada and several other countries. Products include Avance Nerve Graft, off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site. 2Q17 Revenue of $15.2M, up 46% compared to $10.4M in 2Q16.

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

AxoGen AXGN
Rev­enue gen­er­at­ing, ded­i­cat­ed to pe­ripher­al nerve re­pair with a port­fo­lio of re­gen­er­a­tive medicine prod­ucts avai­l­able in the US, Ca­na­da and sev­er­al other coun­tries. Prod­ucts in­clude Avance Nerve... [more in­for­ma­tion]

Location of the Event and Other Places